Results 41 to 50 of about 276,154 (298)
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Embryonal tumors comprise the majority of malignant central nervous system (CNS) neoplasms diagnosed in children under 3 years of age. Compared with their counterparts in older children, these tumors exhibit distinct molecular biology and a more aggressive clinical phenotype, while their management is complicated by the heightened ...
Sudarshawn Damodharan +3 more
wiley +1 more source
ROS-Induced SIRT2 Upregulation Contributes to Cisplatin Sensitivity in Ovarian Cancer
Antioxidants, 2020 Cisplatin resistance remains a significant obstacle for improving the clinical outcome of ovarian cancer patients. Recent studies have demonstrated that cisplatin is an important inducer of intracellullar reactive oxygen species (ROS), triggering cancer ...
Wenyu Wang +8 more
doaj +1 more source
Clinical and Translational Science, 2023 Cisplatin treatment is effective against several types of carcinomas. However, it frequently leads to kidney injury, which warrants effective prevention methods.
Toshihiko Yoshioka +13 more
doaj +1 more source
Journal of Pediatric Hematology/Oncology, 2006 Michael Anne, Gratton, Brendan J, Smyth
europepmc +3 more sources
American Journal of Kidney Diseases, 1986 Cis-dichlorodiammine platinum (II), or cisplatin, has emerged as a principal chemotherapeutic agent in the treatment of otherwise resistant solid tumors and is currently among the most widely used agents in the chemotherapy of cancer. The chief limit to its greater efficacy is its nephrotoxicity, which has made it necessary both to lower its dosage and
R, Safirstein +5 more
openaire +2 more sources
New insight into DNA damage by cisplatin at the atomic scale [PDF]
, 2012 Cisplatin is cis-diamminedichloroplatinum (II) of chemical formula, Pt(NH3)Cl2, abbreviated as cis-DDP and known commercially as platinol. It is used widely as an anticancer drug for various types of cancer, ever since its discovery two centuries ago and
Raji Heyrovska
core
Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer
Molecular Oncology, EarlyView.Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley +1 more source
A low-dose pemetrexed-cisplatin combination regimen induces significant nephrotoxicity in mice
BMC NephrologyBackground Pemetrexed is combined with cisplatin to treat cancer. Whether pemetrexed-cisplatin combination chemotherapy exacerbates cisplatin nephrotoxicity is unclear.
Samson A. Iwhiwhu +6 more
doaj +1 more source
ER-α36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway
Journal of Experimental & Clinical Cancer Research, 2018 Background ER-α36, a novel ER-α66 variant, has been demonstrated to promote tamoxifen resistance in breast cancer cells. However, the role and mechanisms of ER-α36 in cisplatin resistance of breast cancer cells remain unclear. This study investigates the
Linlin Zhu +6 more
doaj +1 more source
Molecular Therapy: Nucleic Acids, 2021 The nuclear receptor-binding SET domain (NSD) protein family encoding histone lysine methyltransferases is involved in cancer progression. However, the role of NSDs in esophageal squamous cell carcinoma (ESCC) remains unclear.
Wenhua Xue +6 more
doaj +1 more source